Waterstone Pharmaceuticals Wuhan

Waterstone Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery and development of novel small molecule drugs for liver and metabolic diseases. Based in Wuhan, China, the company has established a robust pipeline targeting chronic Hepatitis B (HBV) and non-alcoholic steatohepatitis (NASH). A key highlight of their portfolio is the development of Tenofovir amibufenamide (HS-10234), a next-generation HBV treatment licensed to Hansoh Pharma that has reached the commercial stage in China. Waterstone continues to advance internal candidates through its R&D centers, emphasizing improved safety and liver-targeted delivery. The company maintains a dual presence in China and the United States to facilitate global development and strategic partnerships.